$-0.19 EPS Expected for Intec Pharma Ltd. (NTEC)

March 14, 2018 - By Linda Rogers

 $ 0.19 EPS Expected for Intec Pharma Ltd. (NTEC)

Analysts expect Intec Pharma Ltd. (NASDAQ:NTEC) to report $-0.19 EPS on April, 6.They anticipate $0.13 EPS change or 40.63 % from last quarter’s $-0.32 EPS. After having $-0.40 EPS previously, Intec Pharma Ltd.’s analysts see -52.50 % EPS growth. The stock increased 0.77% or $0.05 during the last trading session, reaching $6.55. About 129,122 shares traded. Intec Pharma Ltd. (NASDAQ:NTEC) has risen 51.00% since March 14, 2017 and is uptrending. It has outperformed by 34.30% the S&P500.

Intec Pharma Ltd. (NASDAQ:NTEC) Ratings Coverage

Among 4 analysts covering Intec Pharma (NASDAQ:NTEC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intec Pharma had 9 analyst reports since September 11, 2015 according to SRatingsIntel. The stock has “Buy” rating by Oppenheimer on Thursday, June 22. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) has “Buy” rating given on Thursday, August 10 by Roth Capital. Roth Capital maintained it with “Buy” rating and $9.5000 target in Monday, July 24 report. The company was maintained on Thursday, September 21 by Oppenheimer. Roth Capital initiated it with “Buy” rating and $9.50 target in Friday, September 11 report. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) has “Buy” rating given on Friday, September 11 by TH Capital. The company was initiated on Wednesday, September 16 by Maxim Group. The stock has “Buy” rating by Oppenheimer on Thursday, November 16. On Thursday, August 3 the stock rating was maintained by Roth Capital with “Buy”.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $157.65 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

More notable recent Intec Pharma Ltd. (NASDAQ:NTEC) news were published by: Marketwatch.com which released: “Intec Pharma Ltd.” on October 17, 2017, also Prnewswire.com with their article: “Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa …” published on March 12, 2018, Prnewswire.com published: “Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies” on March 22, 2017. More interesting news about Intec Pharma Ltd. (NASDAQ:NTEC) were released by: Prnewswire.com and their article: “Intec Pharma Granted Patent in Canada for Accordion Pillâ„¢ Carbidopa / Levodopa” published on January 03, 2018 as well as Globes.Co.Il‘s news article titled: “Intec Pharma raising $57.5m on Nasdaq” with publication date: August 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.